Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 144, Issue 8, pp 1445–1462 | Cite as

TIS21/BTG2 inhibits breast cancer growth and progression by differential regulation of mTORc1 and mTORc2–AKT1–NFAT1–PHLPP2 signaling axis

  • Santhoshkumar Sundaramoorthy
  • Preethi Devanand
  • Min Sook Ryu
  • Kye Yong Song
  • Dong Young Noh
  • In Kyoung Lim
Original Article – Cancer Research
  • 172 Downloads

Abstract

Purpose

It has been reported that PI3K/AKT pathway is altered in various cancers and AKT isoforms specifically regulate cell growth and metastasis of cancer cells; AKT1, but not AKT2, reduces invasion of cancer cells but maintains cancer growth. We propose here a novel mechanism of the tumor suppresser, TIS21/BTG2, that inhibits both growth and invasion of triple negative breast cancer cells via AKT1 activation by differential regulation of mTORc1 and mTORc2 activity.

Methods

Transduction of adenovirus carrying TIS21/BTG2 gene and transfection of short interfering RNAs were employed to regulate TIS21/BTG2 gene expression in various cell lines. Treatment of mTOR inhibitors and mTOR kinase assays can evaluate the role of mTORc in the regulation of AKT phosphorylation at S473 residue by TIS21/BTG2 in breast cancer cells. Open data and immunohistochemical analysis were performed to confirm the role of TIS21/BTG2 expression in various human breast cancer tissues.

Results

We observed that TIS21/BTG2 inhibited mTORc1 activity by reducing Raptor-mTOR interaction along with upregulation of tsc1 expression, which lead to significant reduction of p70S6K activation as opposed to AKT1S473, but not AKT2, phosphorylation via downregulating PHLPP2 (AKT1-specific phosphatase) in breast cancers. TIS21/BTG2-induced pAKTS473 required Rictor-bound mTOR kinase, indicating activation of mTORc2 by TIS21/BTG2 gene. Additionally, the TIS21/BTG2-induced pAKTS473 could reduce expression of NFAT1 (nuclear factor of activated T cells) and its target genes, which regulate cancer microenvironment.

Conclusions

TIS21/BTG2 significantly lost in the infiltrating ductal carcinoma, but it can inhibit cancer growth via the TIS21/BTG2tsc1/2–mTORc1–p70S6K axis and downregulate cancer progression via the TIS21/BTG2–mTORc2–AKT1–NFAT1–PHLPP2 pathway.

Keywords

TIS21/BTG2 mTORc1, mTORc2 AKT1 PHLPP2 NFAT1 Triple negative breast cancer 

Abbreviations

BTG2

B-cell translocation gene 2

TIS21

TPA-inducible sequences 21

mTOR

Mammalian target of rapamycin

RICTOR

Rapamycin insensitive companion of mTOR

PI3K

Phosphatidylinositol 3-kinase

S6K1

Ribosomal protein S6 kinase 1

TSC

Tuberous sclerosis complex

PDK1

Phosphoinositide-dependent kinase 1

MEFs

Mouse embryonic fibroblasts

NFAT1

Nuclear factor of activated T cells

PHLPP2

PH domain and leucine rich repeat protein phosphatase 2

Notes

Acknowledgements

This work was supported by the grants from the National R&D Program for Cancer Control (131280) by Ministry for Health and Welfare and by the National Research Foundation (no. 2016R1A2B4006466) of the Korean government MSIP. We deeply appreciate the following scientists for their kind sharing of the materials; recombinant DNAs of GST-S6K1 and GST-AKT1 was a kind gift from professors Sungho Ryu (Pohang University of Science and Technology, South Korea) and Sungkwan An (Konkuk University, South Korea). tsc1−/− and tsc2−/− mouse embryonic fibroblasts were kindly shared by professor Mee-Sup Yoon (Gachon University, South Korea). Torin1 and PP242 were donated by professor Jin Won Cho (Yonsei University, South Korea), AKT inhibitor IV was kindly shared by professor Hong-Duk Youn (Seoul National University College of Medicine, South Korea). We also deeply appreciate professor DY Kang for his statistical analysis.

Funding

This study was funded by National R&D Program for Cancer Control (131280) by Ministry for Health and Welfare and by the National Research Foundation (no. 2016R1A2B4006466).

Compliance with ethical standards

Conflict of interest

The authors declare there is no conflict of interest.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Written informed consent was obtained from all individual participants included in the study.

Supplementary material

432_2018_2677_MOESM1_ESM.docx (80 kb)
Supplementary material 1 (DOCX 79 KB)
432_2018_2677_MOESM2_ESM.pptx (3.2 mb)
Supplementary material 2 (PPTX 3276 KB)

References

  1. Arboleda MJ et al (2003) Overexpression of AKT2/protein kinase B beta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 63:196–206PubMedGoogle Scholar
  2. Bellacosa A, Testa JR, Staal SP, Tsichlis PN (1991) A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254:274–277CrossRefPubMedGoogle Scholar
  3. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR (2005) Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94:29–86.  https://doi.org/10.1016/S0065-230X(05)94002-5 CrossRefPubMedGoogle Scholar
  4. Chen H, Pan H, Qian Y, Zhou W, Liu X (2018) MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2. Mol Cancer 17:4.  https://doi.org/10.1186/s12943-017-0754-0 CrossRefPubMedPubMedCentralGoogle Scholar
  5. Choi JA, Lim IK (2013) TIS21/BTG2 inhibits invadopodia formation by downregulating reactive oxygen species level in MDA-MB-231 cells. J Cancer Res Clin Oncol 139:1657–1665.  https://doi.org/10.1007/s00432-013-1484-3 CrossRefPubMedGoogle Scholar
  6. Choi JA, Jung YS, Kim JY, Kim HM, Lim IK (2016) Inhibition of breast cancer invasion by TIS21/BTG2/Pc3-Akt1-Sp1-Nox4 pathway targeting actin nucleators, mDia genes. Oncogene 35:83–93.  https://doi.org/10.1038/onc.2015.64 CrossRefPubMedGoogle Scholar
  7. Devanand P et al (2014) Inhibition of bladder cancer invasion by Sp1-mediated BTG2 expression via inhibition of DNA methyltransferase 1. FEBS J 281:5581–5601.  https://doi.org/10.1111/febs.13099 CrossRefPubMedGoogle Scholar
  8. Devanand P et al (2018) Inhibition of TNFalpha-interacting protein alpha (Tipalpha)-associated gastric carcinogenesis by BTG2(/TIS21) via downregulating cytoplasmic nucleolin expression. Exp Mol Med 50:e449.  https://doi.org/10.1038/emm.2017.281 CrossRefPubMedPubMedCentralGoogle Scholar
  9. Farioli-Vecchioli S et al (2007) Inhibition of medulloblastoma tumorigenesis by the antiproliferative and pro-differentiative gene PC3. FASEB J 21:2215–2225.  https://doi.org/10.1096/fj.06-7548com CrossRefPubMedGoogle Scholar
  10. Feng J, Park J, Cron P, Hess D, Hemmings BA (2004) Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem 279:41189–41196.  https://doi.org/10.1074/jbc.M406731200 CrossRefPubMedGoogle Scholar
  11. Ficazzola MA, Fraiman M, Gitlin J, Woo K, Melamed J, Rubin MA, Walden PD (2001) Antiproliferative B cell translocation gene 2 protein is down-regulated post-transcriptionally as an early event in prostate carcinogenesis. Carcinogenesis 22:1271–1279CrossRefPubMedGoogle Scholar
  12. Frampton AE et al (2015) Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression. Lancet 385(Suppl 1):S37.  https://doi.org/10.1016/S0140-6736(15)60352-X CrossRefPubMedGoogle Scholar
  13. Gao T, Furnari F, Newton AC (2005) PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18:13–24.  https://doi.org/10.1016/j.molcel.2005.03.008 CrossRefPubMedGoogle Scholar
  14. Guardavaccaro D et al (2000) Arrest of G (1)-S progression by the p53-inducible gene PC3 is Rb dependent and relies on the inhibition of cyclin D1 transcription. Mol Cell Biol 20:1797–1815CrossRefPubMedPubMedCentralGoogle Scholar
  15. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123:725–731.  https://doi.org/10.1007/s10549-009-0674-9 CrossRefPubMedGoogle Scholar
  16. Hong AE, Ryu MS, Kim SJ, Hwang SY, Lim IK (2018) PPAR alpha-target gene expression requires TIS21(/BTG2) gene in liver of the C57BL/6 mice under fasting condition. Mol Cells 41:140–149.  https://doi.org/10.14348/molcells.2018.2257 PubMedPubMedCentralCrossRefGoogle Scholar
  17. Ikenoue T, Hong S, Inoki K (2009) Monitoring mammalian target of rapamycin (mTOR) activity. Methods Enzymol 452:165–180.  https://doi.org/10.1016/S0076-6879(08)03611-2 CrossRefPubMedGoogle Scholar
  18. Jiang WG et al (2005) Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. Eur J Cancer 41:1628–1636.  https://doi.org/10.1016/j.ejca.2005.03.023 CrossRefPubMedGoogle Scholar
  19. Kannan K et al (2001) DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 20:2225–2234.  https://doi.org/10.1038/sj.onc.1204319 CrossRefPubMedGoogle Scholar
  20. Kaunisto A et al (2015) NFAT1 promotes intratumoral neutrophil infiltration by regulating IL8 expression in breast cancer. Mol Oncol 9:1140–1154.  https://doi.org/10.1016/j.molonc.2015.02.004 CrossRefPubMedPubMedCentralGoogle Scholar
  21. Kawakubo H, Carey JL, Brachtel E, Gupta V, Green JE, Walden PD, Maheswaran S (2004) Expression of the NF-kappaB-responsive gene BTG2 is aberrantly regulated in breast cancer. Oncogene 23:8310–8319.  https://doi.org/10.1038/sj.onc.1208008 CrossRefPubMedGoogle Scholar
  22. Kawakubo H et al (2006) Loss of B-cell translocation gene-2 in estrogen receptor-positive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein. Cancer Res 66:7075–7082.  https://doi.org/10.1158/0008-5472.CAN-06-0379 CrossRefPubMedGoogle Scholar
  23. Kim BC, Ryu MS, Oh SP, Lim IK (2008) TIS21/(BTG2) negatively regulates estradiol-stimulated expansion of hematopoietic stem cells by derepressing Akt phosphorylation and inhibiting mTOR signal transduction. Stem Cells 26:2339–2348.  https://doi.org/10.1634/stemcells.2008-0327 CrossRefPubMedGoogle Scholar
  24. Lim IK, Lee MS, Lee SH, Kim NK, Jou I, Seo JS, Park SC (1995) Differential expression of TIS21 and TIS1 genes in the various organs of Balb/c mice, thymic carcinoma tissues and human cancer cell lines. J Cancer Res Clin Oncol 121:279–284CrossRefPubMedGoogle Scholar
  25. Lim IK, Lee MS, Ryu MS, Park TJ, Fujiki H, Eguchi H, Paik WK (1998) Induction of growth inhibition of 293 cells by downregulation of the cyclin E and cyclin-dependent kinase 4 proteins due to overexpression of TIS21. Mol Carcinog 23:25–35CrossRefPubMedGoogle Scholar
  26. Liu M et al (2009) Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. Cell Res 19:828–837.  https://doi.org/10.1038/cr.2009.72 CrossRefPubMedGoogle Scholar
  27. Ma CX et al (2016) A phase I study of the AKT inhibitor MK-2206 in combination with hormonal therapy in postmenopausal women with estrogen receptor-positive metastatic breast cancer. Clin Cancer Res 22:2650–2658.  https://doi.org/10.1158/1078-0432.CCR-15-2160 CrossRefPubMedPubMedCentralGoogle Scholar
  28. Mancini M, Toker A (2009) NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer 9:810–820.  https://doi.org/10.1038/nrc2735 CrossRefPubMedPubMedCentralGoogle Scholar
  29. Manning BD, Toker A (2017) AKT/PKB signaling: navigating the network. Cell 169:381–405.  https://doi.org/10.1016/j.cell.2017.04.001 CrossRefPubMedPubMedCentralGoogle Scholar
  30. Maroulakou IG, Oemler W, Naber SP, Tsichlis PN (2007) Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 67:167–177.  https://doi.org/10.1158/0008-5472.CAN-06-3782 CrossRefPubMedGoogle Scholar
  31. Matsuda S, Rouault J, Magaud J, Berthet C (2001) In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS Lett 497:67–72CrossRefPubMedGoogle Scholar
  32. Melamed J, Kernizan S, Walden PD (2002) Expression of B-cell translocation gene 2 protein in normal human tissues. Tissue Cell 34:28–32.  https://doi.org/10.1054/tice.2001.0220 CrossRefPubMedGoogle Scholar
  33. Messeguer X, Escudero R, Farre D, Nunez O, Martinez J, Alba MM (2002) PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 18:333–334CrossRefPubMedGoogle Scholar
  34. Oki Y et al (2015) Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol 171:463–470.  https://doi.org/10.1111/bjh.13603 CrossRefPubMedPubMedCentralGoogle Scholar
  35. Park TJ et al (2008) TIS21 negatively regulates hepatocarcinogenesis by disruption of cyclin B1-Forkhead box M1 regulation loop. Hepatology 47:1533–1543.  https://doi.org/10.1002/hep.22212 CrossRefPubMedGoogle Scholar
  36. Partovian C, Simons M (2004) Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells. Cell Signal 16:951–957.  https://doi.org/10.1016/j.cellsig.2004.01.008 CrossRefPubMedGoogle Scholar
  37. Persad S et al (2001) Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 276:27462–27469.  https://doi.org/10.1074/jbc.M102940200 CrossRefPubMedGoogle Scholar
  38. Powell E et al (2016) p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer. Breast Cancer Res 18:13.  https://doi.org/10.1186/s13058-016-0673-9 CrossRefPubMedPubMedCentralGoogle Scholar
  39. Rouault JP et al (1996) Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 14:482–486.  https://doi.org/10.1038/ng1296-482 CrossRefPubMedGoogle Scholar
  40. Ryu MS, Lee MS, Hong JW, Hahn TR, Moon E, Lim IK (2004) TIS21/BTG2/PC3 is expressed through PKC-delta pathway and inhibits binding of cyclin B1-Cdc2 and its activity, independent of p53 expression. Exp Cell Res 299:159–170.  https://doi.org/10.1016/j.yexcr.2004.05.014 CrossRefPubMedGoogle Scholar
  41. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101.  https://doi.org/10.1126/science.1106148 CrossRefPubMedGoogle Scholar
  42. Struckmann K, Schraml P, Simon R, Elmenhorst K, Mirlacher M, Kononen J, Moch H (2004) Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma. Cancer Res 64:1632–1638CrossRefPubMedGoogle Scholar
  43. Stupfler B, Birck C, Seraphin B, Mauxion F (2016) BTG2 bridges PABPC1 RNA-binding domains and CAF1 deadenylase to control cell proliferation. Nat Commun 7:10811.  https://doi.org/10.1038/ncomms108 CrossRefPubMedPubMedCentralGoogle Scholar
  44. Sundaramoorthy S, Ryu MS, Lim IK (2013) B-cell translocation gene 2 mediates crosstalk between PI3K/Akt1 and NFkappaB pathways which enhances transcription of MnSOD by accelerating IkappaBalpha degradation in normal and cancer cells. Cell Commun Signal 11:69.  https://doi.org/10.1186/1478-811X-11-69 CrossRefPubMedPubMedCentralGoogle Scholar
  45. Tajima K et al (2015) SETD1A modulates cell cycle progression through a miRNA network that regulates p53 target genes. Nat Commun 6:8257.  https://doi.org/10.1038/ncomms9257 CrossRefPubMedPubMedCentralGoogle Scholar
  46. Takahashi F et al (2011) Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib. Oncogene 30:3084–3095.  https://doi.org/10.1038/onc.2011.24 CrossRefPubMedGoogle Scholar
  47. Treins C, Warne PH, Magnuson MA, Pende M, Downward J (2010) Rictor is a novel target of p70 S6 kinase-1. Oncogene 29:1003–1016.  https://doi.org/10.1038/onc.2009.401 CrossRefPubMedGoogle Scholar
  48. Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A (2005) Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 20:539–550.  https://doi.org/10.1016/j.molcel.2005.10.033 CrossRefPubMedGoogle Scholar
  49. Yoeli-Lerner M, Chin YR, Hansen CK, Toker A (2009) Akt/protein kinase b and glycogen synthase kinase-3beta signaling pathway regulates cell migration through the NFAT1 transcription factor. Mol Cancer Res 7:425–432.  https://doi.org/10.1158/1541-7786.MCR-08-0342 CrossRefPubMedPubMedCentralGoogle Scholar
  50. Yu Y, Dai M, Lu A, Yu E, Merlino G (2018) PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation. Oncogene.  https://doi.org/10.1038/s41388-017-0061-7 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Medical Sciences, BK21 Plus programGraduate School of Ajou UniversitySuwonRepublic of Korea
  2. 2.Department of PathologyChung-Ang University College of MedicineSeoulRepublic of Korea
  3. 3.Department of SurgerySeoul National UniversitySeoulRepublic of Korea
  4. 4.Department of Biochemistry and Molecular BiologyAjou University School of MedicineSuwonRepublic of Korea

Personalised recommendations